Table 1. ESCRT pathway genes mutation across TCGA project on NIH national cancer institute CDC Data Portal database.
| Symbol | ||||||||
|---|---|---|---|---|---|---|---|---|
| CHMP2A | CHMP2B | CHMP3 | CHMP4B | CHMP4C | CHMP5 | CHMP6 | CHMP7 | |
| Project | ||||||||
| SSM (N=530) | ||||||||
| SSM affected cases | 21 | 26 | 15 | 22 | 14 | 19 | 9 | 36 |
| SSM affected cases in TCGA % | 0.0396 | 0.0491 | 0.0283 | 0.0415 | 0.0264 | 0.0358 | 0.017 | 0.0679 |
| CNV (N=510) | ||||||||
| CNV gains | 26 | 11 | 8 | 22 | 14 | 21 | 53 | 3 |
| CNV gains in TCGA % | 0.0510 | 0.0216 | 0.0157 | 0.0431 | 0.0275 | 0.0412 | 0.1039 | 0.0059 |
| CNV losses | 23 | 23 | 9 | 11 | 5 | 5 | 7 | 32 |
| CNV losses in TCGA % | 0.0451 | 0.0451 | 0.0176 | 0.0216 | 0.0098 | 0.0098 | 0.0137 | 0.0627 |
| All SSM affected cases in UCEC | 70 | 59 | 32 | 55 | 31 | 45 | 28 | 68 |
| Somatic mutation | 22 | 35 | 16 | 24 | 19 | 22 | 9 | 43 |
| Somatic mutation in all SSM affected cases in UCEC % | 0.3143 | 0.5932 | 0.5 | 0.4364 | 0.6129 | 0.4888 | 0.3214 | 0.6324 |
| Disease type | ||||||||
| Adenomas and adenocarcinomas | 32 | 31 | 18 | 32 | 21 | 26 | 28 | 40 |
| Cystic, mucinous and serous neoplasms | 38 | 28 | 13 | 23 | 10 | 19 | 0 | 28 |
| Epithelial neoplasms | 1 | |||||||
| Survival | ||||||||
| Dead | 13 | 10 | 5 | 10 | 8 | 14 | 16 | 9 |
| Alive | 57 | 49 | 27 | 45 | 23 | 31 | 51 | 59 |
| Survival rate | 0.82 | 0.72 | 0.81 | 0.76 | 0.68 | 0.65 | 0.25 | 0.84 |
| Interval of last follow-up (Year) | 5.095 | 5.142 | 5.136 | 5.106 | 5.106 | 5.095 | 5.008 | 5.106 |
ESCRT, endosomal sorting complex required for transport; TCGA, The Cancer Genome Atlas; CNV, copy-number variant; SSM, simple somatic mutation; SNV, single nucleotide variation; UCEC, uterine corpus endometrial carcinoma.